A selective transforming growth factor-β ligand trap attenuates pulmonary hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 9, 2016, Pages 1140-1151

  Yung, Lai Ming ^a   Nikolic, Ivana ^a   Paskin Flerlage, Samuel D ^a   Scott Pearsall, R ^b   Kumar, Ravindra ^b   Yu, Paul B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Acceleron Pharma Inc   (United States)

Author keywords

Pulmonary artery; Pulmonary hypertension; Transforming growth factor ; Vascular remodeling; Vascular smooth muscle cells

Indexed keywords

ANTIHYPERTENSIVE AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALDESMON; CALPONIN; HYBRID PROTEIN; INHIBITOR OF DIFFERENTIATION 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; SEMAXANIB; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SMOOTHELIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; LIGAND; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PLASTICITY; CELL PROLIFERATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; HEART FUNCTION; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE PRESSURE; HEART VENTRICLE FUNCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY SMOOTH MUSCLE CELL; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TRANSCRIPTION INITIATION; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEART; HEMODYNAMICS; HYPERTENSION, PULMONARY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HEART; HEMODYNAMICS; HYPERTENSION, PULMONARY; IMMUNOGLOBULIN FC FRAGMENTS; LIGANDS; MALE; MICE, INBRED C57BL; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR REMODELING;

EID: 84994874885     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201510-1955OC     Document Type: Article

References (56)

1. Megalou AJ, Glava C, Oikonomidis DL, Vilaeti A, Agelaki MG, Baltogiannis GG, Papalois A, Vlahos AP, Kolettis TM. Transforming growth factor-b inhibition attenuates pulmonary arterial hypertension in rats. Int J Clin Exp Med 2010;3:332-340.
2. Strelau J, Schober A, Sullivan A, Schilling L, Unsicker K. Growth/differentiation factor-15 (GDF-15), a novel member of the TGF-beta superfamily, promotes survival of lesioned mesencephalic dopaminergic neurons in vitro and in vivo and is induced in neurons following cortical lesioning. J Neural Transm Suppl 2003; (65):197-203.
3. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737-744.
4. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC; International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-84.
5. Waite KA, Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet 2003;4:763-773.
6. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, Hoyng SA, Kawai N, Bloch KD. Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J Biol Chem 2008;283:3877-3888.
7. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002;11:1517-1525.
8. Yu PB, Beppu H, Kawai N, Li E, Bloch KD. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J Biol Chem 2005; 280:24443-24450.
9. Moon JS, Kim SH, Oh SH, Jeong YW, Kang JH, Park JC, Son HJ, Bae S, Park BI, Kim MS, et al. Relaxin augments BMP-2-induced osteoblast differentiation and bone formation. J Bone Miner Res 2014;29:1586-1596.
10. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010;3:88-96.
11. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 2012;185:260-266.
12. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol 1994;144:286-295.
13. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, Shimoda LA, Neptune E, Higgins L, Murphy A, et al. Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 2008;177: 896-905.
14. Chen YF, Feng JA, Li P, Xing D, Zhang Y, Serra R, Ambalavanan N, Majid-Hassan E, Oparil S. Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling. J Appl Physiol (1985) 2006;100:564-571.
15. Sheares KK, Jeffery TK, Long L, Yang X, Morrell NW. Differential effects of TGF-beta1 and BMP-4 on the hypoxic induction of cyclooxygenase-2 in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L919-L927.
16. Graham BB, Chabon J, Gebreab L, Poole J, Debella E, Davis L, Tanaka T, Sanders L, Dropcho N, Bandeira A, et al. Transforming growth factor-b signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation 2013;128:1354-1364.
17. Thomas M, Docx C, Holmes AM, Beach S, Duggan N, England K, Leblanc C, Lebret C, Schindler F, Raza F, et al. Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol 2009;174: 380-389.
18. Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, Steele SJ, Roberts RR, Heier A. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 2011;39:916-924.
19. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661.
20. Shin JA, Hong OK, Lee HJ, Jeon SY, Kim JW, Lee SH, Cho JH, Lee JM, Choi YH, Chang SA, et al. Transforming growth factor-b induces epithelial to mesenchymal transition and suppresses the proliferation and transdifferentiation of cultured human pancreatic duct cells. J Cell Biochem 2011;112:179-188.
21. Azhar M, Runyan RB, Gard C, Sanford LP, Miller ML, Andringa A, Pawlowski S, Rajan S, Doetschman T. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev Dyn 2009;238:431-442.
22. Camenisch TD, Molin DG, Person A, Runyan RB, Gittenberger-de Groot AC, McDonald JA, Klewer SE. Temporal and distinct TGFbeta ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 2002;248:170-181.
23. Saito RA, Watabe T, Horiguchi K, Kohyama T, Saitoh M, Nagase T, Miyazono K. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res 2009;69:2783-2791.
24. Kokudo T, Suzuki Y, Yoshimatsu Y, Yamazaki T, Watabe T, Miyazono K. Snail is required for TGFbeta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 2008;121:3317-3324.
25. Townsend TA, Robinson JY, Deig CR, Hill CR, Misfeldt A, Blobe GC, Barnett JV. BMP-2 and TGFb2 shared pathways regulate endocardial cell transformation. Cells Tissues Organs 2011;194: 1-12.
26. Azhar M, Brown K, Gard C, Chen H, Rajan S, Elliott DA, Stevens MV, Camenisch TD, Conway SJ, Doetschman T. Transforming growth factor Beta2 is required for valve remodeling during heart development. Dev Dyn 2011;240:2127-2141.
27. Townsend TA, Robinson JY, How T, DeLaughter DM, Blobe GC, Barnett JV. Endocardial cell epithelial-mesenchymal transformation requires Type III TGFb receptor interaction with GIPC. Cell Signal 2012;24:247-256.
28. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010;16:1400-1406.
29. Yung LM, Paskin-Flerlage SD, Nikolic I, Pearsall RS, Kumar R, Yu PB. A selective transforming growth factor-b and growth differentiation factor-15 ligand trap attenuates pulmonary hypertension. Presented at the American Heart Association Scientific Sessions. November 7-11, 2014, Chicago, IL. p. A17285.
30. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379-388.
31. Megalou AJ, Glava C, Vilaeti AD, Oikonomidis DL, Baltogiannis GG, Papalois A, Vlahos AP, Kolettis TM. Transforming growth factor-b inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension. Pulm Circ 2012;2: 461-469.
32. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009;119: 566-576.
33. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121: 2747-2754.
34. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008;454: 56-61.
35. King KE, Iyemere VP, Weissberg PL, Shanahan CM. Krüppel-like factor 4 (KLF4/GKLF) is a target of bone morphogenetic proteins and transforming growth factor beta 1 in the regulation of vascular smooth muscle cell phenotype. J Biol Chem 2003;278:11661-11669.
36. Grafe I, Yang T, Alexander S, Homan EP, Lietman C, Jiang MM, Bertin T, Munivez E, Chen Y, Dawson B, et al. Excessive transforming growth factor-b signaling is a common mechanism in osteogenesis imperfecta. Nat Med 2014;20:670-675.
37. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13: 204-210.
38. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114: 1586-1592.
39. Gallo EM, Loch DC, Habashi JP, Calderon JF, Chen Y, Bedja D, van Erp C, Gerber EE, Parker SJ, Sauls K, et al. Angiotensin II-dependent TGF-b signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest 2014;124:448-460.
40. Wu CF, Chiang WC, Lai CF, Chang FC, Chen YT, Chou YH, Wu TH, Linn GR, Ling H, Wu KD, et al. Transforming growth factor b-1 stimulates profibrotic epithelial signaling to activate pericyte-myofibroblast transition in obstructive kidney fibrosis. Am J Pathol 2013;182:118-131.
41. Ling H, Roux E, Hempel D, Tao J, Smith M, Lonning S, Zuk A, Arbeeny C, Ledbetter S. Transforming growth factor b neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One 2013; 8:e54499.
42. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005;313: 943-951.
43. Kim DK, Sheen YY, Jin CH, Park CY, Sreenu D, Rao KS, Krishnaiah M, Subrahmanyam VB. 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors. World Intellectual Property Organization. Patents C07D471/04, A61P25/28, A61P13/12, A61K31/437, A61P19/10, A61P11/00, C07D401/14, C07D413/14 ed. Ewha University-Industry Collaboration Foundation; 2011.
44. Loots GG, Keller H, Leupin O, Murugesh D, Collette NM, Genetos DC. TGF-b regulates sclerostin expression via the ECR5 enhancer. Bone 2012;50:663-669.
45. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, López-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 2001;276: 14588-14596.
46. Brown CB, Boyer AS, Runyan RB, Barnett JV. Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science 1999;283:2080-2082.
47. Blobe GC, Schiemann WP, Pepin MC, Beauchemin M, Moustakas A, Lodish HF, O'Connor-McCourt MD. Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. J Biol Chem 2001;276:24627-24637.
48. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012;302:L363-L369.
49. Wang XB, Wang W, Zhu XC, Ye WJ, Cai H, Wu PL, Huang XY, Wang LX. The potential of asiaticoside for TGF-b1/Smad signaling inhibition in prevention and progression of hypoxia-induced pulmonary hypertension. Life Sci 2015;137:56-64.
50. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009;34: 662-668.
51. Gore B, Izikki M, Mercier O, Dewachter L, Fadel E, Humbert M, Dartevelle P, Simonneau G, Naeije R, Lebrin F, et al. Key role of the endothelial TGF-b/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension. PLoS One 2014;9: e100310.
52. Phillips JA, 3rd, Poling JS, Phillips CA, Stanton KC, Austin ED, Cogan JD, Wheeler L, Yu C, Newman JH, Dietz HC, Loyd JE. Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. Genet Med 2008;10:359-365.
53. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, Jones P, Morrell NW, Jarai G, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182.
54. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-244.
55. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122: 920-927.
56. Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015;21:777-785.